Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.70 |
| ▸ | NOS1 | P29475 | 3/20 | 0.70 |
| ▸ | NOS2 | P35228 | 3/20 | 0.70 |
| ▸ | SLC7A5 | Q01650 | 8/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288850 | 1.00 | NOS3 (0.70) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL29589136 | 1.00 | NOS3 (0.70) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL287831 | 1.00 | NOS3 (0.70) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL20715034 | 0.89 | NOS3 (0.59) | NOS3NOS1NOS2SLC7A5GRIA2 | |
| SCHEMBL6046229 | 0.87 | NOS3 (0.71) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL4629196 | 0.86 | NOS3 (0.53) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL3152192 | 0.85 | NOS3 (0.73) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL20502934 | 0.85 | NOS3 (0.73) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL20502933 | 0.85 | NOS3 (0.73) | NOS3NOS1NOS2SLC7A5PTGS1 | |
| SCHEMBL8075751 | 0.83 | NOS3 (0.50) | NOS3NOS1NOS2CASRITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5874472-A | Aminoacid derivatives as no synthase inhibitors | GLAXO WELLCOME INC. (US) | 1999-02-23 | — | — | US | claimed |
| EP-0705257-B1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | WELLCOME FOUND (GB) | 1998-03-11 | — | — | EP | claimed |
| EP-0705257-A1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-04-10 | — | — | EP | claimed |
| WO-1995000505-A1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-01-05 | — | — | WO | claimed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2024252336-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | PEPTIDREAM INC. (JP) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PEPTIDREAM INC. (JP) | 2024-01-11 | — | — | US | disclosed |
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-4276096-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | PeptiDream Inc. (JP) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022149610-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | ペプチドリーム株式会社 | 2022-07-14 | — | — | WO | disclosed |
| EP-3981784-A1 | REGULATORS OF CELL DIVISION | Technische Universität Dresden (DE) | 2022-04-13 | — | — | EP | disclosed |
| US-6649593-B1 | Amino acid derivatives including serine, leucine, valine, arginine, asparginine, methionine, glycine and phenylalanine units; S1 protease inhibition; modulation of cholesterol homeostasis in cells | TULARIK INC. | 2003-11-18 | — | — | US | disclosed |
| WO-2001027138-A2 | MODULATORS OF SREBP PROCESSING | TULARIK INC. (US) | 2001-04-19 | — | — | WO | disclosed |
| US-5874472-A | Aminoacid derivatives as no synthase inhibitors | GLAXO WELLCOME INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0705257-B1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | WELLCOME FOUND (GB) | 1998-03-11 | — | — | EP | disclosed |
| EP-0705257-A1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-04-10 | — | — | EP | disclosed |
| WO-1995000505-A1 | AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391828-A1 | REGULATORS OF CELL DIVISION | PCNA, BOD1L1, MKI67 | NOS3 3629/4885NOS1 3182/4885NOS2 3515/4885 |
| US-20240010627-A1 | NOVEL GUANIDINE DERIVATIVE AND METHOD FOR PRODUCING SAME | GMPS, MAPT, UROD | NOS3 599/4885NOS1 351/4885NOS2 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.